相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adoption of Gene Expression Profile Testing and Association With Use of Chemotherapy Among Women With Breast Cancer
Michael J. Hassett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The impact of the 21-gene recurrence score assay on decision making about adjuvant chemotherapy in early-stage estrogen-receptor-positive breast cancer in an oncology practice with a unified treatment policy
D. B. Geffen et al.
ANNALS OF ONCOLOGY (2011)
Impact of the 21-Gene Recurrence Score Assay Compared With Standard Clinicopathologic Guidelines in Adjuvant Therapy Selection for Node-Negative, Estrogen Receptor-Positive Breast Cancer
Jessica F. Partin et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Economic evaluation of the 21-gene signature (Oncotype DXA®) in lymph node-negative/positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03)
Masahide Kondo et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20
Gong Tang et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Factors Influencing Treatment Recommendations in Node-Negative Breast Cancer
Elisabeth Edstrom Elder et al.
JOURNAL OF ONCOLOGY PRACTICE (2011)
Utility of Oncotype DX Risk Estimates in Clinically Intermediate Risk Hormone Receptor-Positive, HER2-Normal, Grade II, Lymph Node-Negative Breast Cancers
Catherine M. Kelly et al.
CANCER (2010)
Breast Cancer Multidisciplinary Team Adjuvant Therapy Decision Making and Adjuvant! Online
V. Nowak et al.
CLINICAL ONCOLOGY (2010)
Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection
Shelly S. Lo et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost-Effectiveness Analysis of Recurrence Score-Guided Treatment Using a 21-Gene Assay in Early Breast Cancer
Daphne T. Tsoi et al.
ONCOLOGIST (2010)
Economic Implications of 21-Gene Breast Cancer Risk Assay from the Perspective of an Israeli-Managed Health-Care Organization
Shmuel H. Klang et al.
VALUE IN HEALTH (2010)
Health-state utility values in breast cancer
Tessa Peasgood et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2010)
Recommendations from the EGAPP Working Group: can tumor gene expression in patients with breast cancer?
Alfred O. Berg et al.
GENETICS IN MEDICINE (2009)
The Influence of a Gene Expression Profile on Breast Cancer Decisions
Leonard R. Henry et al.
JOURNAL OF SURGICAL ONCOLOGY (2009)
Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
Michael Drummond et al.
VALUE IN HEALTH (2009)
Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer?
Juhi Asad et al.
AMERICAN JOURNAL OF SURGERY (2008)
Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-Medicare data
Michael E. Stokes et al.
VALUE IN HEALTH (2008)
Cost-effectiveness of switching to exemestane after 2 to 3 years of therapy with tamoxifen in postmenopausal women with early-stage breast cancer
David Thompson et al.
VALUE IN HEALTH (2007)
Health related quality of life in different states of breast cancer
Mathias Lidgren et al.
QUALITY OF LIFE RESEARCH (2007)
Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer
Ruth Oratz et al.
JOURNAL OF ONCOLOGY PRACTICE (2007)
Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer - An economic analysis based on prognostic and predictive validation studies
Gary H. Lyman et al.
CANCER (2007)
Patient time costs associated with cancer care
K. Robin Yabroff et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Can differences in breast cancer utilities explain disparities in breast cancer care?
Mark D. Schleinitz et al.
JOURNAL OF GENERAL INTERNAL MEDICINE (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer
Soonmyung Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The cost of adjuvant chemotherapy in patients with early-stage breast carcinoma
N Oestreicher et al.
CANCER (2005)
Work absence after breast cancer diagnosis:: a population-based study
M Drolet et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2005)
Gene expression profiling and breast cancer care: What are the potential benefits and policy implications?
N Oestreicher et al.
GENETICS IN MEDICINE (2005)
Economic outcomes of breast cancer survivorship: CALGB study 79804
ML Hensley et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
